- Transcenta Therapeutics has entered a strategic collaboration and non-exclusive licensing agreement with EirGenix to license its HiCB continuous bioprocessing platform.
- EirGenix plans to deploy the technology across its biologics development and CDMO operations, with Transcenta eligible for upfront, milestone and royalty payments.
Transcenta Therapeutics has announced a strategic collaboration and non-exclusive licensing agreement with EirGenix Inc., covering the use of Transcenta’s Highly Intensified Continuous Bioprocessing (HiCB) platform. The agreement enables EirGenix to access Transcenta’s continuous perfusion and hybrid continuous purification technologies, alongside process documentation, know-how and regulatory support.
Under the terms of the deal, Transcenta will grant EirGenix rights to apply the HiCB platform across biologics development and manufacturing activities. Transcenta is eligible to receive upfront and milestone payments, as well as future royalties linked to commercial use of the licensed technologies.
The HiCB platform is designed to improve process efficiency, enhance process control and product consistency, and reduce cost of goods compared with conventional fed-batch manufacturing. According to the companies, these attributes are intended to support broader access to high-quality biologics by enabling more efficient production.
EirGenix plans to implement the HiCB platform within its biologics programmes and to offer the technology to customers through its CDMO and contract manufacturing services, targeting clients seeking intensified and continuous manufacturing solutions.
“By enabling others to implement HiCB, we can collectively advance affordability of and global access to innovative biologics.”
Dr Xueming Qian, Chairman and CEO of Transcenta
